SEC Form 4 · accession 0000899243-18-006002

Emergent BioSolutions Inc. · EBS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Fuad El-Hibri

Officer — Chairman · Director · 10% Owner

Period of report

Feb 27, 2018

Accepted (ET)

Mar 1, 2018 · 8:49 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001367644

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Feb 27, 2018	M	9,794	—	A	1,540,010	D
Common Stock	Feb 27, 2018	F	2,385	$49.64	D	1,537,625	D
Common Stock^F1	Feb 28, 2018	M	9,723	—	A	1,547,348	D
Common Stock	Feb 28, 2018	F	2,368	$49.97	D	1,544,980	D
Common Stock^F2	holding	—	—		—	4,344,250	I	By Intervac, L.L.C.
Common Stock^F3	holding	—	—		—	1,524,155	I	By Biovac, L.L.C.

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Restrictive Stock Units^F1,F4	—	Feb 27, 2018	A	19,288	A	—	—	Common Stock	19,288	81,352	D
Employee Stock Options (Right to Buy)^F5	$49.64	Feb 27, 2018	A	38,577	A	—	Feb 26, 2025	Common Stock	38,577	38,577	D
Restrictive Stock Units^F1,F6	—	Feb 27, 2018	M	9,794	D	—	—	Common Stock	9,794	71,558	D
Restrictive Stock Units^F1,F7	—	Feb 28, 2018	M	9,723	D	—	—	Common Stock	9,723	61,835	D

Explanation of responses

F1Restricted stock units convert into common stock on a one-for-one basis.
F2Mr. El-Hibri's wife, individually, and Mr. and Mrs. El-Hibri, as tenants by the entirety, collectively hold an aggregate 40.65% equity interest in Intervac, L.L.C., which in turn is the direct owner of 4,344,250 shares of the Issuer's common stock. Mr. El-Hibri disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Intervac, L.L.C. for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein.
F3Mr. El-Hibri, individually, and Mr. and Mrs. El-Hibri, as tenants by the entirety, collectively hold an aggregate 89.2% equity interest in Biovac, L.L.C, which in turn is the direct owner of 1,524,155 shares of the Issuer's common stock. Mr. El-Hibri disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Biovac, L.L.C. for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein.
F4On February 27, 2018, Mr. El-Hibri was granted 19,288 restricted stock units vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date.
F5On February 27, 2018, Mr. El-Hibri was granted 38,577 stock options vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date.
F6On February 28, 2017, Mr. El-Hibri was granted 29,382 restricted stock units vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date.
F7On March 1, 2016, Mr. El-Hibri was granted 29,167 restricted stock units (after giving effect to the adjustment in connection with the Issuer's spin-off of Aptevo Therapeutics Inc.) vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date.